Q-omics provides the consensus-scored ZNF841 profile across patient tissues and cancer cell-line models. ZNF841 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF841 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, ZNF841 RNA expression shows 21,004 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where ZNF841 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF841 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF841 survival associations across molecular data types. ZNF841 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF841 RNA expression–survival associations across cancer types. High ZNF841 expression shows unfavorable associations in MESO, KIRP, KIRC and LGG, but favorable associations in BLCA and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF841 RNA expression.
This table summarizes ZNF841 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF841. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF841 shows higher tumor expression in KIRC, COAD, HNSC, BLCA, LIHC and STAD. The KIRC box plot shows higher ZNF841 RNA expression in tumor versus normal tissue (log2 FC = +0.726, t-test p < 0.001).
This table shows molecular features associated with ZNF841 in patient tissues and cancer cell lines. In patient samples, ZNF841 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF841 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
